We are committed to serving the best interests of our shareholders.

PRESS RELEASES

Date Title and Summary Additional Formats
Toggle Summary TESARO Initiates Registrational Development Program for Anti-PD-1 Antibody TSR-042
TSR-042 is the first TESARO immuno-oncology candidate to enter a registration program Ongoing clinical trial expanded to enroll patients with endometrial cancer Patient-centric administration schedule  with every 6 week dosing WALTHAM, Mass., April 27, 2017 (GLOBE NEWSWIRE) -- TESARO, Inc.
View HTML
Toggle Summary TESARO Announces Approval of VARUBY® (Oral Rolapitant Tablets) by European Commission
VARUBY provides protection for delayed chemotherapy-induced nausea and vomiting (CINV) with a single dose as part of an antiemetic regimen Up to 50% of patients undergoing highly or moderately emetogenic chemotherapy experience delayed CINV even when prescribed a 5-HT 3 receptor antagonist and
View HTML
Toggle Summary Tesaro Announces Participation in Two Investor Conferences
WALTHAM, Mass., April 25, 2017 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, today announced its participation in two upcoming investor conferences. The two conferences are: The Leerink Boston Biopharma Bus Tour on Wednesday, May 10, 2017.
View HTML
Toggle Summary TESARO to Announce First-Quarter 2017 Financial Results on May 9, 2017
WALTHAM, Mass., April 25, 2017 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO) will announce its first-quarter 2017 financial results on Tuesday, May 9, 2017, after the close of the U.S. financial markets. TESARO's senior management team will host a conference call and live audio webcast at 4:15
View HTML
Toggle Summary TESARO Announces Availability of Zejula™ (Niraparib) for Patients With Recurrent Ovarian Cancer in the U.S.
ZEJULA is the first and only PARP inhibitor to be approved for the maintenance treatment of women with recurrent ovarian cancer ZEJULA is the only PARP inhibitor that has demonstrated a clinically meaningful increase in PFS regardless of BRCA mutation or biomarker status WALTHAM, Mass., April 19,
View HTML
Toggle Summary Tesaro Wins Awards for Clinical Development Team of the Year and Clinical Partnership of the Year
WALTHAM, Mass., April 07, 2017 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, has been recognized with two Clinical and Research Excellence (CARE) Awards. Pharma/Biotech Product Development Team of the Year was awarded to the niraparib development
View HTML
Toggle Summary TESARO Announces Expanded Development Program for Niraparib Focused on the Treatment of Front-Line Metastatic Ovarian and Lung Cancers and Metastatic Breast Cancer
Expanded niraparib ovarian cancer program intended to potentially transform the treatment of front-line ovarian cancer New breast cancer clinical program for niraparib to address greatest area of unmet need and broader patient population BRAVO trial no longer expected to serve as a registration
View HTML
Toggle Summary TESARO Announces U.S. FDA Approval of ZEJULA™ (niraparib) for Women with Recurrent Ovarian Cancer
TESARO ANNOUNCES U.S. FDA APPROVAL OF ZEJULA &#8482 (NIRAPARIB) FOR WOMEN WITH RECURRENT OVARIAN CANCER
View HTML
Toggle Summary Tesaro Announces Presentation of Niraparib Phase 3 ENGOT-OV16/NOVA Trial Secondary Endpoint Results During SGO
NATIONAL HARBOR, Md., March 13, 2017 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, today announced the presentation of secondary endpoint results from the Phase 3 ENGOT-OV16/NOVA trial of niraparib at the 2017 Society for Gynecologic Oncology (SGO)
View HTML
Toggle Summary TESARO Announces Niraparib Data Presentations at the 2017 SGO Annual Meeting on Women's Cancer
WALTHAM, Mass., March 12, 2017 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, today announced two niraparib presentations at the 2017 Society for Gynecologic Oncology (SGO) Annual Meeting on Women's Cancer, March 12 to 15, 2017, in National Harbor,
View HTML